Linezolid Fresenius Kabi (Linezolid)

Linezolid works by binding to the bacterial 50S ribosomal subunit, preventing the formation of the initiation complex needed for protein synthesis. This inhibition stops bacterial growth, providing a bacteriostatic effect against most susceptible organisms and a bactericidal effect at higher concentrations.

The prescribed dose of linezolid is determined by the treating physician based on the type and severity of infection, patient weight, renal and hepatic function, and other clinical factors. Dosing recommendations are provided in the product labeling and should be followed as directed by a qualified healthcare professional.

Safety data for linezolid in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risks and benefits with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Linezolid is often compared with vancomycin, another agent active against MRSA. Unlike vancomycin, linezolid is available in both oral and intravenous forms, has excellent lung penetration, and does not require therapeutic drug monitoring. However, linezolid carries a risk of hematologic toxicity and serotonin syndrome, whereas vancomycin is associated with nephrotoxicity and requires serum level monitoring.

Linezolid Fresenius Kabi should be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside the recommended range.

The product is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional using aseptic technique, typically over a period of 30‑60 minutes, depending on the clinical protocol and patient tolerance.

Serious adverse events include thrombocytopenia, peripheral neuropathy, optic neuritis, and serotonin syndrome, especially when combined with serotonergic medications. Patients should be monitored regularly for blood‑count changes, visual disturbances, and signs of excessive serotonergic activity such as agitation, hyperreflexia, or hyperthermia.

Linezolid is contraindicated in patients with a known hypersensitivity to linezolid or any component of the formulation. Caution is advised for individuals currently receiving monoamine oxidase inhibitors, serotonergic agents, or those with a history of severe myelosuppression. Clinical judgment should guide use in these populations.